Compared with single Tamoxifen, or Fulvestrant, or Erastin treatment, the combination of the two drugs further inhibited the growth of ER+ breast cancer cells (Fig. 5I, S2B), indicating that inducing ferroptosis by targeting xc− can increase the sensitivity of ER+ breast cancer cells in response to endocrine therapy. The gene discussed is ESR1; the disease is breast carcinoma.